In blood banking and transfusion medicine, the distinction between phenotype and genotype is fundamental. The two terms are often confused, but they describe different aspects of blood group expression, and both have direct clinical implications.
Definition: Observable characteristics
In Blood Banking: Which antigens are detected on red cells
Example: D+, C+, c+, E-, e+
Testing Method: Serological (antibody reactions)
What It Shows: Current antigen expression
Definition: Genetic makeup
In Blood Banking: Specific alleles in DNA
Example: RHD*01, RHCE*Ce/RHCE*ce
Testing Method: Molecular (DNA analysis)
What It Shows: Inherited genetic information
Phenotype refers to the observable characteristics. In blood banking, this means which antigens can be detected on red blood cells by serological testing. A result of D+, C+, c+, E-, e+ describes the phenotype: what can be seen and measured directly.
Genotype, on the other hand, represents the actual genetic makeup: the specific alleles present in an individual's DNA. The genotype determines the phenotype, but the relationship isn't always straightforward. For example, the phenotype D+ could result from genotypes containing different RHD alleles, while D- typically results from RHD gene deletion.
Blood group nomenclature can be confusing because several systems exist:
Modern molecular reports typically use ISBT nomenclature, which is more precise for describing genetic variants.
In routine blood transfusion, phenotype matching is usually sufficient. A D-negative patient receives D-negative blood to prevent alloimmunisation. However, genotype becomes crucial in several scenarios:
Anti-D haemolytic disease of the fetus and newborn (HDFN) can only occur when the mother is D-negative and the fetus is D-positive. A D-negative mother (for example dce/dce) can pass on only an RHD-negative haplotype, so the fetus's D type depends on the father:
A father's most probable genotype from serology is only an estimate. You can see that estimate for a given phenotype using the RhMPG calculator. In UK practice, the fetus's RhD type is predicted directly by cell-free fetal DNA testing of maternal blood, and this is used to target anti-D immunoglobulin.
In cases of recent transfusion, phenotyping can be misleading because donor cells may still be circulating. The mixed cell population makes serological testing unreliable. Genotyping from DNA extracted from white blood cells provides the patient's true blood group genetics, unaffected by transfused red cells.
While genotyping is invaluable post-transfusion, some phenotyping may still be possible using specialised laboratory techniques such as adsorption and elution studies, though these are technically demanding and time-consuming.
| Scenario | Phenotyping | Genotyping | Preferred Method |
|---|---|---|---|
| Routine transfusion | Accurate | Not needed | Phenotyping |
| Recent transfusion | Unreliable | Accurate | Genotyping |
| Pregnancy planning | Limited info | Complete info | Both |
| Weak D evaluation | Ambiguous | Definitive | Genotyping |
The weak D phenotype illustrates why understanding both phenotype and genotype is important. These individuals have reduced D antigen expression, appearing D-negative or giving weak reactions in standard testing. The most common weak D types (1, 2 and 3) are generally managed as D-positive once RHD genotyping has confirmed the type; until then, women of childbearing potential are managed as D-negative.
Without genotyping, these patients might be inappropriately managed, either wasting D-negative blood or risking sensitisation.
Molecular genotyping can identify specific weak D types, distinguishing those who can receive D-positive blood from those who might form anti-D antibodies. This precision avoids unnecessary use of D-negative red cells, which come from about 15% of donors of European ancestry and a much smaller share in many other populations.
Understanding genotypes allows prediction of inheritance patterns. Parents with known genotypes can be counselled about possible blood types in their children. This knowledge is valuable for family planning and directed donation scenarios.
Parents: Mother dce/dce (D-negative), father DCe/dce (D-positive, heterozygous for D)
| Father: DCe | Father: dce | |
|---|---|---|
| Mother: dce | DCe/dce (50%) |
dce/dce (50%) |
Offspring probabilities: 50% DCe/dce (D-positive); 50% dce/dce (D-negative).
Clinical significance: Each pregnancy has a 50% chance of a D-positive baby. If the mother has no anti-D, a D-positive pregnancy carries a risk of sensitisation, which anti-D immunoglobulin prophylaxis is given to prevent.
Genotype information is particularly valuable for:
Advances in molecular biology have made genotyping more accessible and practical for clinical use:
Cell-free fetal DNA testing allows determination of fetal RHD status from maternal blood as early as 10 weeks gestation. This technology is particularly valuable for:
Note: In the UK, high-throughput fetal RHD genotyping is offered by many maternity services following NICE diagnostics guidance DG25 (2016). Results may be less reliable in some populations because of RHD variants.
Modern platforms can simultaneously test for multiple blood group systems, providing comprehensive profiles useful for patients requiring chronic transfusions. This technology is particularly valuable for patients with sickle cell disease or thalassaemia who benefit from extensive antigen matching.
| Technology | Application | Turnaround Time | Relative Cost* |
|---|---|---|---|
| Real-time PCR | Targeted variants (e.g., weak D typing) | 2-4 hours | £ |
| Microarray | Multiple blood group systems | 24-48 hours | ££ |
| Next-generation sequencing | Comprehensive analysis, novel variants | 3-5 days | £££ |
*Cost ranges vary significantly by institution and geographic location
↑ Back to Top